|
| Press Releases |
|
 |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
|
エーザイ、米国臨床腫瘍学会年次総会において抗体薬物複合体farletuzumab ecteribulinの最新の知見を発表 |
| エーザイ、米国臨床腫瘍学会年次総会において抗体薬物複合体farletuzumab ecteribulinの最新の知見を発表 more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
| Tuesday, July 14, 2020 |
|
|
エーザイとバイオジェン、BAN2401についてプレクリニカル（無症状期）アルツハイマー病を対象とした新たな臨床第III相試験（AHEAD 3-45）を開始 |
| Alzheimer's Clinical Trials Consortium、エーザイ株式会社とバイオジェン・インクは、このたび、抗アミロイドB（AB）プロトフィブリル抗体BAN2401 について、臨床症状は正常で、AD のより早期ステージにあたる脳内 AB蓄積が陽性*のプレクリニカル AD および脳内 AB蓄積が境界域レベルの早期プレクリニカル AD を対象とした臨床第III相試験（AHEAD 3-45）を米国において開始したことをお知らせします。 more info >> |
|
|
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease |
| The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe. more info >> |
|
| Monday, July 13, 2020 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded |
| Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization. more info >> |
|
| Friday, July 10, 2020 |
|
|
エーザイ、Toll様受容体研究の実用化による全身性エリテマトーデス治療薬の創製をめざした産学官共同研究開発契約を締結し、研究活動を開始 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社を代表研究機関とする研究プロジェクト「産学連携オールジャパン体制による本邦Toll様受容体研究の実用化:全身性エリテマトーデス薬の創製」について、日本において4つの大学との間で産学官共同研究開発契約を締結しましたのでお知らせします。 more info >> |
|
| Thursday, July 9, 2020 |
|
|
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an investigational treatment for Alzheimer's disease. more info >> |
|
|
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱重工サーマルシステムズ、海外市場向けビル用マルチエアコンのラインアップを追加
Jan 16, 2026 13:30: JST
|
|
|
三菱商事、米国テキサス州・ルイジアナ州における ヘインズビルシェールガス事業への参画について
Jan 16, 2026 13:00: JST
|
|
|
三菱造船が開発した自動操船システム“SUPER BRIDGE-X”を搭載 世界初 旅客船における自動運転レベル4相当での商用運航開始
Jan 16, 2026 13:00: JST
|
|
|
興業銀行成功發行全市場首單自貿區主體「玉蘭債」
Jan 16, 2026 10:04 HKT/SGT
|
|
|
First three HKTDC trade fairs of 2026 draw some 82,000 international buyers
Jan 15, 2026 19:46 HKT/SGT
|
|
|
NEC Launches "NEC Composable Disaggregated Infrastructure Solution" for Distributed Computing Resources
Jan 15, 2026 17:00 JST
|
|
|
真正的賦能者——愛格法醫療於2026年歐洲放射學會議（ECR）展現影像創新風采
Jan 15, 2026 16:00 HKT/SGT
|
|
|
真正的赋能者——爱克发医疗在2026年欧洲放射学大会上展现影像创新力量
Jan 15, 2026 16:00 HKT/SGT
|
|
|
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 2026
Jan 15, 2026 16:00 HKT/SGT
|
|
|
OPPO Appoints Stagwell (STGW) Agencies in Singapore: Allison Worldwide for PR and Influencer; Assembly for Media
Jan 15, 2026 14:00 HKT/SGT
|
|
|
マツダ、「フレア」を商品改良
Jan 15, 2026 13:00: JST
|
|
|
KKR、アジアのプライベート・クレジット投資向けに25億米ドルを調達
Jan 15, 2026 10:00: JST
|
|
|
Casa Minerals Inc. Announces Non-Brokered Private Placement Raising $800,000
Jan 15, 2026 01:29 HKT/SGT
|
|
|
沙特阿拉伯公共投資基金與紅海鋁業控股有限公司簽署初步條款
Jan 14, 2026 22:06 HKT/SGT
|
|
|
沙特阿拉伯公共投资基金与红海铝业控股有限公司签署初步条款
Jan 14, 2026 22:06 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
